Form 4: Tandem Diabetes Care EVP & CFO Leigh Vosseller Receives Significant Equity Awards

Tandem Diabetes Care Inc.'s Executive Vice President and Chief Financial Officer, Leigh Vosseller, was granted 31,486 Performance Stock Units and 31,488 Restricted Stock Units on May 30, 2025, as part of the company's long-term incentive plan.

Summary

• Leigh Vosseller, Executive Vice President and Chief Financial Officer of Tandem Diabetes Care Inc. (TNDM), received equity awards on May 30, 2025.
• The awards consist of 31,486 Performance Stock Units (PSUs) and 31,488 Restricted Stock Units (RSUs).
• The PSUs are contingent on achieving pre-defined company performance metrics by December 31, 2027, with the potential number of shares issued ranging from 0% to 200% of the awarded amount.
• The RSUs will vest as to 33% of the total shares on May 15, 2026, with the remaining shares vesting in eight equal quarterly installments thereafter.
• These awards were granted under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended.
• Following these transactions, Ms. Vosseller directly owns 33,798 shares of common stock and indirectly owns 11,860 shares through the Leigh A. Vosseller Trust, in addition to the newly awarded PSUs and RSUs.

Sentiment

Score: 7

Explanation: The filing indicates a standard executive equity award, which is generally positive for aligning management incentives with shareholder interests, but it does not contain new operational or financial performance data that would significantly alter sentiment beyond this routine aspect.

Positives

• The grant of significant equity awards to a key executive (EVP & CFO) aligns management's interests with long-term shareholder value.
• Performance Stock Units (PSUs) are tied to specific company performance metrics, incentivizing the achievement of strategic goals and potentially driving future growth.
• Restricted Stock Units (RSUs) provide retention incentives through multi-year vesting schedules, helping to secure key talent.

Risks

• The actual number of shares received from PSUs could be zero if minimum performance metrics are not met by December 31, 2027.
• Vesting of both PSUs and RSUs is contingent on the awardee's continuing service through the respective vesting and measurement dates.

Future Outlook

The equity awards are part of a long-term incentive plan, indicating the company's strategy to align executive compensation with future performance and shareholder value creation. The PSUs are tied to performance through December 31, 2027, and the RSUs are designed for ongoing executive retention.

Management Comments

• "Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan)."
• "Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date)."
• "The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest."
• "Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan."
• "RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter."

Industry Context

This filing represents a standard executive compensation practice in publicly traded companies, particularly within the medical device and healthcare technology sectors like diabetes care. It reflects a common strategy to incentivize long-term performance and retain key talent by aligning executive interests with shareholder returns over a multi-year horizon.

Comparison to Industry Standards

• The utilization of both Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) is a prevalent practice in executive compensation packages across the medical device and broader technology industries, mirroring approaches taken by companies such as Dexcom (DXCM) or Insulet (PODD).
• The RSU vesting schedule, with an initial 33% vesting after approximately one year followed by quarterly installments, is typical for retention-focused equity awards in the industry.
• The performance-based structure of the PSUs, allowing for a payout range of 0% to 200% based on specific metrics, aligns with best practices for linking executive compensation directly to company performance, a common feature in growth-oriented healthcare companies.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Achievement of pre-defined performance metrics for PSUs by December 31, 2027, to determine the final number of shares to be issued.
• Vesting of RSUs, with the first tranche on May 15, 2026, followed by eight equal quarterly installments thereafter.

Key Dates

Recommendation

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Transaction, Equity Award, Performance Stock Units, Restricted Stock Units, Executive Compensation, Leigh Vosseller, CFO, Long-Term Incentive Plan, Diabetes Care